Literature DB >> 30504359

Evidence-based management of immune thrombocytopenia: ASH guideline update.

Cindy E Neunert1, Nichola Cooper2.   

Abstract

In 1996 and 2011, the American Society of Hematology (ASH) supported efforts to create guidelines for the diagnosis and management of patients with immune thrombocytopenia (ITP). These guidelines used different approaches to arrive at recommendations for testing and treatment. Despite differences in methodology, in both cases there was a paucity of randomized trials to inform recommendations. As data on the diagnosis and management of ITP expands, the ASH Committee on Quality is dedicated to maintaining updated guidelines representing recent evidence and guideline methodology. Here, we will review the updated ASH guidelines on ITP with a focus on recommendations with new understanding and future research to close knowledge gaps.
© 2018 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30504359      PMCID: PMC6245979          DOI: 10.1182/asheducation-2018.1.568

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  51 in total

1.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

2.  Long-term results of splenectomy in adult chronic immune thrombocytopenia.

Authors:  Yue Guan; Shixuan Wang; Feng Xue; Xiaofan Liu; Lei Zhang; Huiyuan Li; Renchi Yang
Journal:  Eur J Haematol       Date:  2016-11-07       Impact factor: 2.997

3.  High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial.

Authors:  Yu Wei; Xue-bin Ji; Ya-wen Wang; Jing-xia Wang; En-qin Yang; Zheng-cheng Wang; Yu-qi Sang; Zuo-mu Bi; Cui-ai Ren; Fang Zhou; Guo-qiang Liu; Jun Peng; Ming Hou
Journal:  Blood       Date:  2015-10-19       Impact factor: 22.113

4.  Splenectomy in children with chronic ITP: long-term efficacy and relation between its outcome and responses to previous treatments.

Authors:  Ugo Ramenghi; Giovanni Amendola; Loredana Farinasso; Paola Giordano; Giuseppe Loffredo; Bruno Nobili; Silverio Perrotta; Giovanna Russo; Marco Zecca
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

5.  Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

Authors:  V Blanchette; P Imbach; M Andrew; M Adams; J McMillan; E Wang; R Milner; K Ali; D Barnard; M Bernstein
Journal:  Lancet       Date:  1994-09-10       Impact factor: 79.321

6.  Laparoscopic splenectomy for primary immune thrombocytopenia: clinical outcome and prognostic factors.

Authors:  Jorge Montalvo; David Velazquez; Juan P Pantoja; Mauricio Sierra; Xavier López-Karpovitch; Miguel F Herrera
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2014-06-06       Impact factor: 1.878

7.  Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China.

Authors:  Tingting Wang; Maoqiang Xu; Linxiang Ji; Renchi Yang
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

8.  Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Authors:  James B Bussel; David J Kuter; Vinod Pullarkat; Roger M Lyons; Matthew Guo; Janet L Nichol
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

9.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

10.  Total remission of severe immune thrombocytopenia after short term treatment with romiplostim.

Authors:  Efthymia Vlachaki; Vaia Papageorgiou; Filippos Klonizakis; Maria Spandonidou; Sofia Chisan; Evaggelia Vetsiou; Elissavet Ioannidou
Journal:  Hematol Rep       Date:  2011-10-27
View more
  9 in total

1.  The child with immune thrombocytopenia: to treat or not to treat, is that still the question?

Authors:  Nichola Cooper; Douglas B Cines
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

2.  Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States.

Authors:  Leah J McGrath; Karynsa Kilpatrick; Robert A Overman; Diane Reams; Anjali Sharma; Ivy Altomare; Jeffrey Wasser; M Alan Brookhart
Journal:  Clin Epidemiol       Date:  2020-05-05       Impact factor: 4.790

Review 3.  [What are the indications for rescue procedures? : Systemic rheumatic diseases in the intensive care unit].

Authors:  B Hellmich; C Löffler
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

4.  Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia.

Authors:  Shuwen Wang; Xiaoyu Zhang; Shaoqiu Leng; Qirui Xu; Zi Sheng; Yanqi Zhang; Jie Yu; Qi Feng; Ming Hou; Jun Peng; Xiang Hu
Journal:  Front Immunol       Date:  2021-01-05       Impact factor: 7.561

Review 5.  Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.

Authors:  Nicola Vianelli; Giuseppe Auteri; Francesco Buccisano; Valentina Carrai; Erminia Baldacci; Cristina Clissa; Daniela Bartoletti; Gaetano Giuffrida; Domenico Magro; Elena Rivolti; Daniela Esposito; Gian Marco Podda; Francesca Palandri
Journal:  Ann Hematol       Date:  2022-02-24       Impact factor: 4.030

6.  Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.

Authors:  Monica Carpenedo; Erminia Baldacci; Claudia Baratè; Alessandra Borchiellini; Francesco Buccisano; Giuseppina Calvaruso; Federico Chiurazzi; Bruno Fattizzo; Gaetano Giuffrida; Elena Rossi; Francesca Palandri; Potito Rosario Scalzulli; Sergio Mario Siragusa; Angelantonio Vitucci; Francesco Zaja
Journal:  Ther Adv Hematol       Date:  2021-10-09

7.  Identification and verification of differentially expressed key genes in peripheral blood-derived T cells between chronic immune thrombocytopenia patients and healthy controls.

Authors:  Bingjie Ding; Liu Liu; Yingtong Dai; Mengjuan Li; Ao Xia; Xuewen Song; Jianping Liu; Xiaoran Wang; Yongping Song; Hu Zhou
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

8.  Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study.

Authors:  Adam Rosenberg; Catelyn Cashion; Fariya Ali; Harini Haran; Raaj K Biswas; Vivien Chen; Helen Crowther; Jennifer Curnow; Elyssa Deakin; Chee-Wee Tan; Yi Ling Tan; Andrew Vanlint; Christopher M Ward; Robert Bird; David J Rabbolini
Journal:  Res Pract Thromb Haemost       Date:  2022-09-18

Review 9.  Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.

Authors:  Candida Vitale; Maria Chiara Montalbano; Chiara Salvetti; Elia Boccellato; Valentina Griggio; Mario Boccadoro; Marta Coscia
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.